Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies,
are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC …

Executive summary Liver disease in the UK stands out as the one glaring exception to the
vast improvements made during the past 30 years in health and life expectancy for chronic …

Primary liver cancer, the majority of which are hepatocellular carcinomas, is now the second
leading cause of cancer death worldwide. Hepatocellular carcinoma is a unique cancer that …

Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. A
single‐nucleotide polymorphism (SNP), rs6834314, was associated with serum liver …

Abstract β‐Catenin, the downstream effector of the Wnt signaling, plays important roles in
hepatic development, regeneration, and tumorigenesis. However, its role at hepatocyte …

Abstract Background and Aim Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic
steatohepatitis (NASH) account for a large and growing proportion of liver disease burden …

Background & Aims We determined the optimal HCV treatment prioritization strategy for
interferon-free (IFN-free) HCV direct-acting antivirals (DAAs) by disease stage and risk …

Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide.
Interferon has been the major antiviral treatment, yielding viral clearance in approximately …

Background & Aims Prevention of hepatitis C virus (HCV) transmission among people who
inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of …

Australia was one of the first countries to introduce government-funded unrestricted access
to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However …